News Release


 

Licensing Agreement Cancelled for NST-141 Agent for Pruritus in Atopic Dermatitis (09/03/2012)

Taiho Pharmaceutical Co., Ltd. (HQ: Tokyo, President: Toru Usami) announced today that the licensing agreement with Nippon Shinyaku Co., Ltd. (HQ: Kyoto, President: Shigenobu Maekawa) for the new NST-141 agent for pruritus in atopic dermatitis has been cancelled by mutual consent.

Discovered by Nippon Shinyaku Co., Ltd., NST-141 is a new antipruritic agent for external administration. The said agreement covering joint development and collaborative marketing in Japan had been concluded on October 1, 2008.


<< Back